B · Normal
[The first domestically produced long-acting respiratory syncytial virus preventive monoclonal antibody is approved] On September 4, Simcere Pharmaceuticals announced that the domestic Class 1 bio-innovative drug Culevibizumab Injection (trade name: Inmulac), a strategic collaboration between it and Ruiyang (Shandong) Biopharmaceutical Co., Ltd., was approved for marketing by the National Medical Products Administration, becoming China’s first domestically produced long-acting preventive monoclonal antibody against respiratory syncytial virus (RSV) approved for marketing.
medicine 🕐 2026-09-04 19:43
#biopharmaceutical #clone #Virus #medicine #Pharmaceutical business
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Oracle and Wipro cooperate to strengthen end-to-end pharmacovigilance services] 09-22 20:16 [Jiangsu: From January to August, the added value of industries above designated 09-22 11:22 [Novo Nordisk: Create a new business segment called blood and endocrine diseases 09-21 16:23 September 21st, Novo Nordisk stated that it plans to expand its production capac 09-21 16:06 September 21st, Novo Nordisk aims to have sales of product lines under developme 09-21 16:06 [Two departments: Pilot project for electronic customs clearance of imported dru 09-21 11:28

Comments

0/500
Captcha (click to refresh)
No comments yet